Stifel analyst Thomas Stephan lowered the firm’s price target on Alphatec (ATEC) to $20 from $24 and keeps a Buy rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec Holdings Announces Board Director Retirement and Changes
- Alphatec Earnings Call Highlights Growth And Margins
- Alphatec: Buy Rating Reaffirmed on Consistent Outperformance, Differentiated Technology, and Supportive Valuation
- Alphatec: Strengthening Earnings Leverage and Market Share Underscore Attractive Buy-Rated Risk/Reward
- Alphatec reports Q4 adjusted EPS 6, consensus 4c